Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Emyria.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Emyria on a high after getting ethics approval, Twiggy’s investment
Health & Biotech
Twiggy’s Tattarang is getting into health tech – which ASX stocks will benefit?
Health & Biotech
ASX Health Stocks: Emyria takes its MDMA-inspired drugs to the next level
Health & Biotech
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs
Health & Biotech
ASX Health Stocks: Ansell commits to net zero by 2040, but says Scope 3 needs more work
News
Market highlights and 5 ASX small caps to watch on Monday
Health & Biotech
Could Aussie cannabinoid companies help solve a global opioid crisis?
Health & Biotech
Weed Week: Sydney Uni says it’s okay to CBD ‘n drive, and cannabis-infused drinks on the rise
Health & Biotech
ASX Health Stocks: Anteris implants its novel aortic valve DurAVR into 8 more patients
Health & Biotech
ASX Health Stocks: Vectus jumps 13pc on promising Phase 1 study results
Mining
Lessons from the Masters: Here’s how Twiggy Forrest spreads his investments
News
Closing Bell: Markets go easy peasy lemon squeezy on Anthony Norman Albanese
Health & Biotech
ASX Health Stocks: Ecstasy for Emyria in MDMA trial, Beamtree wins US$7m deal
Health & Biotech
Weed Week: Wastewater doesn’t lie, Aussie cannabis consumption increased in 2021
Health & Biotech
4D Medical CEO hails launch of world’s first dedicated lung scanner, stock price jumps 30pc
News
Weed Week: New Yorkers with cannabis convictions first in line for retail licences, CBX Stock Exchange launches
Health & Biotech